Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

telatinib

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Purpose: Pseudomyogenic hemangioendothelioma (PHE) is an extremely rare locally aggressive neoplasm with endothelial… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2017
Review
2017
Despite advancements in therapy for advanced gastric and gastroesophageal junction cancers, their prognosis remains dismal. Tumor… Expand
  • figure 1
2014
2014
Multidrug resistance (MDR) is a phenomenon where cancer cells become simultaneously resistant to anticancer drugs with different… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2014
Review
2014
The phenomenon of multidrug resistance (MDR) has attenuated the efficacy of anticancer drugs and the possibility of successful… Expand
  • figure 1
  • figure 2
  • figure 3
2011
2011
BACKGROUND Blocking both receptor and ligand of the vascular endothelial growth factor (receptor) VEGF(R) pathway might be… Expand
2010
2010
Purpose: We studied the safety and tolerability of telatinib, an orally available, small-molecule tyrosine kinase inhibitor of… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2009
2009
PURPOSE Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of vascular endothelial growth factor receptor… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
2009
2009
SummaryPurpose Telatinib is an orally active small-molecule tyrosine kinase inhibitor of kinase insert domain receptor (KDR… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2008
Highly Cited
2008
Purpose: Hypertension is a commonly reported side effect in antiangiogenic therapy. We investigated the hypothesis that telatinib… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
2008
2008
Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2